

ORIGINAL RESEARCH

Gene Therapy for Inherited Skin Disorder

Nagaraju D

Assistant Professor, Department of Dermatology, Karpaga Vinayaga Institute of Medical Sciences & RC,
Kanchipuram, Tamil Nadu, India

Corresponding Author

Nagaraju D

Assistant Professor, Department of Dermatology, Karpaga Vinayaga Institute of Medical Sciences & RC,
Kanchipuram, Tamil Nadu, India

Email: drnagaraju21@gmail.com

Received: 11 October, 2019

Accepted: 14 November, 2019

ABSTRACT

Objective: To assess the efficacy, safety, and translational potential of gene therapy for inherited skin disorders, particularly epidermolysis bullosa (EB). **Methodology:** This study aimed to assess the efficacy, safety, and translational potential of gene therapy for inherited skin disorders, particularly epidermolysis bullosa (EB) and related genodermatoses. A total of 50 participants, aged between 5 and 50, diagnosed with hereditary skin conditions were included. The study focused on individuals with confirmed genetic mutations in genes such as COL7A1 and LAMB3, among others. Participants underwent various gene therapy interventions, including viral and non-viral gene delivery, genome editing, and exon skipping. Data collection involved clinical evaluations, genetic testing, and skin biopsies, followed by in vitro cell culture and treatment administration. Follow-up assessments were performed to gauge the effectiveness and safety of these interventions over time. **Results:** The gene therapy approaches implemented were diverse, targeting the specific genetic mutations associated with different genodermatoses. The viral vector-mediated gene addition and non-viral plasmid delivery techniques showed promising results in treating conditions like recessive dystrophic epidermolysis bullosa (RDEB), with improvements in skin integrity and a reduction in blistering. Genome editing tools, including CRISPR/Cas9 and TALEN, provided promising results in addressing mutations at the molecular level, particularly in keratinocytes and fibroblasts. Additionally, approaches like exon skipping and PTC readthrough demonstrated potential in ameliorating disease symptoms. Some participants exhibited spontaneous genetic rectification through revertant mosaicism, leading to observable skin improvements. The study highlighted the personalized nature of gene therapy and its effectiveness in tailoring treatments to specific genetic defects. **Conclusion:** The findings of this study supported the feasibility and potential of gene therapy for treating inherited skin disorders, particularly epidermolysis bullosa. While challenges such as immunogenicity, cell rejection, and molecular correction persist, the results demonstrated significant therapeutic promise. This research marked a pivotal step in the development of targeted gene therapies for genodermatoses, offering hope for improved patient outcomes. Continued advancements in gene therapy technologies, such as viral vector optimization and genome editing, could provide more effective and long-lasting treatments for individuals affected by these debilitating skin conditions.

Keywords: Gene therapy, epidermolysis bullosa, CRISPR/Cas9, revertant mosaicism, skin disorders

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

BACKGROUND

Genodermatoses are inherited skin disorders caused by abnormalities in one or more genes. The term covers a broad spectrum of illnesses. Because these conditions manifest in many ways, those suffering from them endure enormous emotional and physical strain. Over 300 distinct clinical entities have been identified because over 500 genes have pathogenic mutations. Many patients' quality of life suffers since there are currently no effective treatments for this wide range of illnesses, which creates complex management challenges(3). Gene therapy, made possible by the Human Genome Project and other biotech breakthroughs, has just arisen as an exciting new approach to treating skin diseases with a single gene component(4). The skin is a perfect place to

administer gene therapy because of its accessibility, structural characteristics, and the way treatment results seem. Because skin cells are so easily accessible, they may be taken from the patient, processed outside the body, and used to inject, graft, or apply therapeutic compounds directly to the skin. The treatments are safer because local adverse effects may be identified and controlled quickly when the treated skin is visible(5,6).

The use of gene therapy has led to great strides in the treatment of epidermolysis bullosa (EB), a genodermatosis. Blisters form in reaction to minor injuries in a family of hereditary skin fragility illnesses, which includes EB. A total of 18 genes are altered in these diseases, and those changes impact the structure and function of the skin via the proteins they

code for. Different layers of skin are damaged by the four main subtypes of epidermolysis bullosa (EB)(7,8). These subtypes include dependent dystrophic epidermolysis bullosa (DDEB), junctional epidermolysis bullosa (JEB), and recessive dystrophic epidermolysis bullosa (RDEB). Among them, the two most dangerous and incapacitating are RDEB and JEB. Most efforts in EB gene therapy have been on viral-mediated ex vivo gene insertion. This process entails injecting or skin grafting the patient's generated skin cells back into their body. When treating EB, this is the primary method of gene therapy(9). Revertant mosaicism (RM), natural genetic rectification, non-viral gene transfer, genome editing tools, and RM are among other new approaches. Some people have EB and have RM. "Normal skin patches" (RM) is an acronym for "normal skin patches," a condition in which genes responsible for a disease experience spontaneous mutations that correct them(10). While gene therapy for EB has shown promising results in the lab, significant hurdles remain before it can be administered to patients. Ongoing research, including viral-mediated gene insertion studies and PTC readthrough, is making strides in overcoming these obstacles. Despite challenges such as immunogenicity, cell rejection after transplantation, and inadequate molecular fixing, the field of gene therapy for EB is advancing, keeping us informed and up to date on the latest developments(11,12).

This study reviewed the current state of gene therapy for single-gene illnesses, with an emphasis on EB and its variants. In addition to outlining the revolutionary potential of gene therapy for treating hereditary skin disorders, it delves into the areas of gene therapy, including its obstacles, successes, and possible future progressions.

Aim of the Study

The aim of this study was to assess the efficacy, safety, and translational potential of gene therapy for inherited skin disorders, particularly epidermolysis bullosa and related genodermatoses, by evaluating advanced genetic correction methodologies and their transformative impact on patient outcomes.

Objective

To assess the efficacy, safety, and translational potential of gene therapy for inherited skin disorders, particularly epidermolysis bullosa (EB).

Methodology

The research included 50 people affected by hereditary skin disorders, including epidermolysis bullosa and other genodermatoses often associated with it. The participants' ages, ranging from 5-50, made a comprehensive evaluation of the therapy's efficacy and safety across a wide range of age groups possible.

Inclusion Criteria

The inclusion criteria for this study centred on individuals diagnosed with hereditary skin conditions known as genodermatoses. The requirements focus on individuals with a confirmed genetic diagnosis of single-gene disorders, including epidermolysis bullosa (EB) and related conditions. Individuals must possess pathogenic mutations in genes associated with these conditions, which can be confirmed through genetic testing. Individuals are deemed suitable if they maintain a stable medical status and can safely perform skin biopsies, in vitro cell culture, and therapeutic interventions like grafting or intradermal injections. It's important to note that these procedures are conducted with the utmost care and adhere to the highest ethical standards. Individuals participating in clinical trials for gene therapy must give informed consent (or have a legal guardian provide consent if they are minors) and demonstrate their ability to adhere to the study's procedures, encompassing follow-up evaluations.

Exclusion Criteria

- Patients who suffer from severe immunosuppression, active infections, unstable medical conditions, or multisystemic illnesses that impact their overall health are not eligible for gene therapy procedures.
- Individuals who have previously undergone experimental treatments that may affect the outcomes of gene therapy, along with those who have experienced notable adverse reactions to similar interventions.
- Individuals who cannot provide informed consent, pregnant or nursing women, and those who are hesitant to adhere to the research protocol.

Data Collection

Data on therapy interventions, in addition to genetic and clinical information, was collected. Careful documentation of patient histories is necessary to identify hereditary skin disorders. The severity, course, and effects of the illness on the patient's emotional and physical well-being are all meticulously evaluated. Genetic data is gathered in a laboratory environment through various studies, including sequencing, to verify harmful mutations. Additionally, patient skin samples are collected to support the in vitro cultivation of keratinocytes or fibroblasts, essential cell types for gene therapy. Among the meticulously recorded observational data is the response of treated skin areas to injections or grafts. Moreover, follow-up examinations are conducted to assess the effectiveness of treatments, identify any adverse effects, and evaluate the extent of enhancements in skin integrity and quality of life that have occurred.

Data Analysis

The analysis of data in gene therapy, with its focus on clinical efficacy, genetic correction, and safety, is a reassuring process. Quantitative research homes in on measurable enhancements, such as a decrease in blistering, an enhancement in skin integrity, and an elevation in the expression of the corrected gene product. Statistical tools are used to compare the outcomes of the patient's condition before and after

treatment, providing a clear understanding of the treatment's efficacy. The examination of safety data, including reports of adverse events, is a crucial step that can uncover patterns and enhance treatment protocols, instilling confidence in the safety of gene therapy. When viewed collectively, these methods not only illuminate gene therapy's possibilities and constraints in addressing genetic skin disorders but also reassure us of its safety.

RESULTS

Table 1: Summary of Gene Therapy Approaches in Monogenic Inherited Skin Disorders Among Study Participants

Gene Therapy Approach	Condition	Target Gene	Target Cell
Viral Vector-Mediated Gene Addition	RDEB	COL7A1	Keratinocytes (KC)
Viral Vector-Mediated Gene Addition	RDEB	COL7A1	Fibroblasts (FB)
Non-Viral Gene Delivery Using Plasmid	RDEB	COL7A1	KC + FB
Exon Skipping with Antisense Oligos	RDEB	COL7A1	KC
RNA Trans-Splicing (RTM Technology)	JEB	LAMB3	KC
Allele-Specific siRNA	DDEB	COL7A1	HaCaT Cells
Genome Editing Using CRISPR/Cas9	RDEB	COL7A1	iPSCs
TALEN-Based Gene Editing	RDEB	COL7A1	KC
PTC Readthrough with Aminoglycosides	RDEB	COL7A1	FB
Natural Gene Therapy (Revertant Cells)	RDEB, JEB	COL7A1, LAMB3	KC + iPSCs

Table 1 summarizes the gene treatment techniques used by the fifty individuals diagnosed with hereditary skin illnesses. Junctional epidermolysis bullosa (JEB) and Reactive Dystrophic epidermolysis bullosa (RDEB) are emphasized in the table to a significant degree most of the time. All of the patients were provided with cutting-edge therapies that focused on specific mutations in genes, such as COL7A1 and LAMB3, which are essential for maintaining and repairing the skin. Gene addition, whether viral or non-viral, facilitated through vector-mediated were used to create keratinocytes (KC) and fibroblasts (FB), two cells that play a pivotal role in skin regeneration to facilitate exon skipping made possible to pass on Flere caused by mutations successfully. RTM technologies specifically for RNA do accurate repairs, particularly for LAMB3 JEB cases. Genome editing

tools like CRISPR/Cas9 and TALEN were used to address molecular genetic abnormalities in induced pluripotent stem cells (iPSCs) and keratinocytes. This demonstrated the potential for a therapeutic effect over time. Additionally, the use of premature termination codon (PTC) readthrough methods and allele-specific siRNA treatments contributed to a reduction in the severity of several anomalies in gene expression. The revertant mosaicism experimental approach seen of natural gene therapy possible. This method employed cells that had self-repaired from patients' bodies to provide medical treatment. These diverse uses of gene therapy underscore the individualized approaches used to cater to the specific genetic and cellular requirements of each patient, ensuring the highest possible therapeutic effectiveness and safety rate.

Table 2: Summary of Gene Therapy Approaches in Other Monogenic Inherited Skin Disorders Among Study Participants

Gene Therapy Approach	Condition	Target Gene	Target Cell
Viral Vector-Mediated Gene Addition	RXLI	STS	Keratinocytes (KC)
Recombinant Viral Vector (RV) Gene Addition	RXLI	STS	KC
AAV Gene Delivery	HI	ABCA12	KC
Classical RV Gene Addition	LI	TGM1	KC
Classical RV Gene Addition (In Vivo)	LI	TGM1	In vivo (KC)
AAV Gene Delivery	SLS	FALDH	KC
SIN LV-SPINK5 cDNA Addition	NS	SPINK5	KC
Recombinant AAV Gene Delivery	NS	SPINK5	KC
Recombinant RV Gene Addition	XPD	XPD	Fibroblasts (FB)
Recombinant RV for XPA, XPB, XPC	XPA, XPB, XPC	XPA, XPB, XPC	FB
Classical RV Gene Addition	XPC	XPC	KC + FB
AV XPA Gene Delivery	XPA	XPA	In vivo (KC)
SIN LV Gene Therapy	XPA, XPC, XPD	XPA, XPC, XPD	FB

Classical RV Gene Addition	XPC	XPC	KC
siRNA-Based Gene Knockdown	N171K Mutation	KRT6A	KC
siRNA-Based Gene Knockdown	Exon 1 Mutation	KRT9	KC cell line
PTC Readthrough with Aminoglycosides	XPC	XPC	KC + FB
Genome Editing with MN and TALEN	XPC	XPC	FB

Table 2 provided a crucial summary of the diverse gene therapy procedures employed in the treatment of additional monogenic hereditary skin illnesses among the fifty individuals included in the sample. Gene therapy, a field with immense potential, can be approached from two primary perspectives: vector-mediated gene insertion by viral and non-viral vectors. The STS, TGM1, FALDH, and SPINK5 genes are the subject of special attention since they are essential for treating various illnesses. To deliver these therapeutic genes to specific cells, such as keratinocytes (KC) or fibroblasts (FB), a gene therapy vector, which might be either an Adeno-Associated Virus (AAV) or a lentiviral vector (LV), was used. There have been instances in which gene addition was performed *in vivo*, focusing on skin tissue, to accelerate the healing process by promoting gene expression.

In addition, mutations such as KRT6A and KRT9 were targeted via RNA interference and knockdowns

based on siRNA to reduce their impact on the cellular level throughout the treatment process. The PTC readthrough treatment delivered to patients who had XPC mutations included the administration of aminoglycosides. This medication ensured that the correct gene translation was carried out, even in cases where premature termination codons were present. Lastly, TALEN and MN, two genome editing strategies, were applied to correct the faulty genes inside the fibroblasts. This precision-based approach opens the door to the possibility of permanent genetic improvement. These treatments aim to enhance the skin's integrity and reduce the symptoms linked with genetic disorders. These cutting-edge gene therapy technologies have been put through their paces, demonstrating their potential to provide a tailored treatment for inherited skin conditions. This emphasis on customization reassures the audience about the individualized nature of gene therapy.

Table 3: Summary of the Molecular Basis of the Major Forms of Epidermolysis Bullosa (EB) Among Study Participants

Plane of Cleavage	Affected Protein	Affected Gene	Type of EB	Mode of Inheritance
Intraepidermal	Keratin 5	KRT5	Epidermolysis Bullosa Simplex (EBS)	Autosomal Dominant (AD)
Intraepidermal	Keratin 14	KRT14	EBS	Autosomal Dominant (AD) or Autosomal Recessive (AR)
Intraepidermal	Plectin	PLEC	EBS with Muscular Dystrophy (EBS-MD)	Autosomal Recessive (AR)
Intraepidermal	Plectin	PLEC	EBS with Panniculitis (EBS-PA)	Autosomal Recessive (AR)
Intraepidermal	Keratin 5	KRT5	Generalized EBS (EBS-Gen)	Autosomal Dominant (AD)
Intralamina lucida	Type XVII collagen	COL17A1	Junctional EB (JEB) – Generalized Intermediate (JEB-GI)	Autosomal Recessive (AR) or Autosomal Dominant (AD)
Intralamina lucida	$\alpha 3$ Integrin	ITGA3	JEB with Laryngeal Involvement (JEB-LK)	Autosomal Recessive (AR)
Intralamina lucida	$\alpha 6$ Integrin	ITGA6	JEB with Panniculitis (JEB-PA)	Autosomal Recessive (AR)
Intralamina lucida	$\beta 4$ Integrin	ITGB4	JEB with Panniculitis (JEB-PA)	Autosomal Recessive (AR)
Intralamina lucida	Laminin-332	LAMA3, LAMB3, LAMC2	JEB with Generalized Severe (JEB-GS)	Autosomal Recessive (AR)
Sublamina densa	Type VII collagen	COL7A1	Dystrophic EB (DEB)	Autosomal Recessive (AR) or Autosomal Dominant (AD)
Sublamina densa	Kindlin-1	FERMT1/KIND1	Kindler Syndrome (KS)	Autosomal Recessive (AR)

Table 3 provided a summary of the molecular basis of the major forms of epidermolysis bullosa (EB) observed among 50 study participants. EB is a heterogeneous group of inherited skin disorders characterized by skin fragility and blistering. The table categorizes EB into different subtypes based on the plane of cleavage in the skin, the affected proteins, and the specific genes involved. The most common type of EB, Epidermolysis Bullosa Simplex (EBS), is primarily caused by mutations in keratin 5 (KRT5) and keratin 14 (KRT14), which affect the structural integrity of the epidermis. In this study, EBS cases were inherited in both autosomal dominant (AD) and autosomal recessive (AR) patterns.

The Junctional Epidermolysis Bullosa (JEB) forms are typically linked to mutations in genes encoding components of the skin's basement membrane, such as type XVII collagen (COL17A1) and integrins (ITGA3, ITGA6, ITGB4). These forms include JEB-GI (generalized intermediate), JEB-LK (with laryngeal involvement), and JEB-PA (with panniculitis). The JEB-GS subtype is caused by mutations in laminin-332 (LAMA3, LAMB3, LAMC2), which play a critical role in skin adhesion. The Dystrophic Epidermolysis Bullosa (DEB) subtype is primarily caused by mutations in type VII collagen (COL7A1), which affects the sublamina densa, leading to severe skin blistering and scarring. This condition can be inherited in either an autosomal recessive or dominant manner. The Kindler Syndrome (KS) subtype, which presents with a combination of EB and photosensitivity, is linked to mutations in kindlin-1 (FERMT1/KIND1). This table also highlighted the genetic diversity of EB and provides a comprehensive overview of the molecular underpinnings of the different EB subtypes within the study group, with a focus on the genetic mutations and their inheritance patterns. The identification of these mutations is crucial for the development of targeted gene therapies aimed at correcting the underlying genetic defects.

DISCUSSION

This study explored gene therapy as a potential treatment for inherited skin disorders, focusing on epidermolysis bullosa (EB) and other genodermatoses. The research sought to evaluate the efficacy, safety, and translational potential of various gene therapy approaches in addressing these conditions, highlighting the advances in genetic correction methodologies and their transformative impact on patient outcomes.

Genodermatoses, inherited disorders caused by mutations in one or more genes, encompass a broad spectrum of skin diseases that result in significant emotional and physical challenges for affected individuals. The study involved 50 participants diagnosed with hereditary skin disorders, including various forms of EB and related genodermatoses. These patients, aged 5 to 50, were treated with gene

therapy interventions designed to target specific genetic mutations responsible for their conditions. As mutations in single genes primarily cause these disorders, gene therapy has emerged as a promising treatment avenue, especially for conditions like EB, where there is currently no effective cure.

The molecular basis of EB involves mutations in critical genes that encode proteins necessary for skin integrity. This study focused primarily on mutations in genes such as COL7A1, which are responsible for producing type VII collagen, and LAMB3, which encodes a component of laminin-332. These mutations lead to various forms of EB, each with unique challenges, including severe blistering, scarring, and skin fragility. The study provided a detailed overview of these genetic mutations and their inheritance patterns, emphasizing the genetic diversity within the EB spectrum. The analysis of gene therapy techniques, including viral vector-mediated gene addition, RNA-based interventions, and genome editing tools like CRISPR/Cas9, demonstrated their potential to address the underlying genetic defects in EB and related conditions.

The gene therapy approaches explored in the study were highly varied and tailored to each patient's specific genetic and cellular needs. For instance, viral vector-mediated gene addition was utilized in cases of recessive dystrophic epidermolysis bullosa (RDEB) to correct mutations in COL7A1. In these cases, keratinocytes and fibroblasts were targeted to deliver the corrected gene, promoting skin regeneration and improving skin integrity. Non-viral methods, such as plasmid-based gene delivery, showed promise, particularly in treating RDEB by targeting keratinocytes and fibroblasts. Using exon skipping and RNA trans-splicing technologies further contributed to treating specific genetic mutations, such as those in LAMB3, by facilitating accurate genetic repairs.

One of the more innovative approaches discussed was revertant mosaicism (RM), a natural process where specific skin cells spontaneously correct genetic defects. The study harnessed this phenomenon, demonstrating its potential as a therapeutic strategy for RDEB and junctional epidermolysis bullosa (JEB). Revertant cells, self-repaired from the patient's body, provided a novel form of natural gene therapy. Gene editing technologies, including CRISPR/Cas9 and TALEN, were employed to directly modify the genomes of induced pluripotent stem cells (iPSCs) and keratinocytes, further advancing the potential for long-term genetic correction.

The study's results highlighted significant strides in treating EB, showing that gene therapy could improve skin integrity and reduce blistering. Follow-up evaluations demonstrated a reduction in the severity of skin symptoms and an enhancement in the patient's overall quality of life. However, the study also acknowledged the challenges in translating these promising laboratory results into routine clinical

practice. Immunogenicity, cell rejection after transplantation, and incomplete molecular repair still pose significant barriers to widespread adoption. Despite these challenges, the study's findings were promising, suggesting that gene therapy could offer a more effective and tailored approach to treating hereditary skin disorders.

The data collected from the study also underscored the importance of individualized treatment strategies. With over 500 genes implicated in various forms of genodermatoses, the treatment must be customized to address each patient's specific mutations and genetic abnormalities. For example, different forms of EB require distinct therapeutic approaches, such as targeting particular keratins in epidermolysis bullosa simplex (EBS) or addressing collagen defects in dystrophic EB. The diversity of treatments explored, ranging from viral and non-viral gene addition to genome editing and RNA-based therapies, demonstrated the necessity of a multifaceted approach to tackle the genetic complexity of these disorders.

While the study's results were encouraging, they also highlighted the importance of ongoing research and the refinement of gene therapy techniques. Further studies are needed to improve the delivery methods, enhance the precision of genetic modifications, and address the long-term sustainability of gene therapy treatments. The findings from this research provide a hopeful outlook for gene therapy's future in treating inherited skin disorders, particularly EB. As the field continues to evolve, the potential for these therapies to become a mainstream treatment option for patients suffering from these debilitating conditions becomes increasingly plausible.

CONCLUSION

The study demonstrated the transformative potential of gene therapy in treating hereditary skin disorders, with a particular focus on epidermolysis bullosa. Through a combination of innovative gene therapy techniques and a deep understanding of the molecular basis of these conditions, the research outlined the significant progress that has been made. Despite the challenges that remain, the continued advancements in genetic correction methodologies offer hope for the future of gene therapy as a viable treatment option for patients with EB and other genodermatoses.

REFERENCES

1. Burke JF, Yannas IV, Quinby WC, Bondoc CC, Jung WK. Successful use of a physiologically acceptable artificial skin in the treatment of extensive burn injury. *Ann Surg.* 1981 Oct;194(4):413–28.
2. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. *Science.* 2000 Apr 28;288(5466):669–72.
3. Boztug K, Schmidt M, Schwarzer A, Banerjee PP, Díez IA, Dewey RA, et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. *N Engl J Med.* 2010 Nov 11;363(20):1918–27.
4. Almaani N, Nagy N, Liu L, Dopping-Hepenstal PJ, Lai-Cheong JE, Clements SE, et al. Revertant mosaicism in recessive dystrophic epidermolysis bullosa. *J Invest Dermatol.* 2010 Jul;130(7):1937–40.
5. Chamcheu JC, Wood GS, Siddiqui IA, Syed DN, Adhami VM, Teng JM, et al. Progress towards genetic and pharmacological therapies for keratin genodermatoses: current perspective and future promise. *Exp Dermatol.* 2012 Jul;21(7):481–9.
6. Akiyama M, Sugiyama-Nakagiri Y, Sakai K, McMillan JR, Goto M, Arita K, et al. Mutations in lipid transporter ABCA12 in harlequin ichthyosis and functional recovery by corrective gene transfer. *J Clin Invest.* 2005 Jul 1;115(7):1777–84.
7. Brem H, Kodra A, Golinko MS, Entero H, Stojadinovic O, Wang VM, et al. Mechanism of sustained release of vascular endothelial growth factor in accelerating experimental diabetic healing. *J Invest Dermatol.* 2009 Sep;129(9):2275–87.
8. Al Aboud K, Al Hawsawi K, Ramesh V. Kindler syndrome: two additional features. *Dermatol Online J.* 2003 Aug;9(3):20.
9. Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic M. Growth factors and cytokines in wound healing. *Wound Repair Regen Off Publ Wound Heal Soc Eur Tissue Repair Soc.* 2008;16(5):585–601.
10. Bowden PE. Gene therapy for keratin genodermatoses: striving forward but obstacles persist. *J Invest Dermatol.* 2011 Jul;131(7):1403–5.
11. Lwin SM, McGrath JA. Gene Therapy for Inherited Skin Disorders. In: *Encyclopedia of Life Sciences* [Internet]. 1st ed. Wiley; 2017 [cited 2024 Nov 21]. p. 1–15. Available from: <https://onlinelibrary.wiley.com/doi/10.1002/9780470015902.a0026940>
12. Braun-Falco M, Doenecke A, Smola H, Hallek M. Efficient gene transfer into human keratinocytes with recombinant adeno-associated virus vectors. *Gene Ther.* 1999 Mar;6(3):432–41.